Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.51 |
| ▸ | CA1 | P00915 | 5/20 | 0.51 |
| ▸ | CA9 | Q16790 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | AR | P10275 | 1/20 | 0.50 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 3/20 | 0.41 |
| ▸ | CA6 | P23280 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA5A | P35218 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL579071 | 0.84 | CA2 (0.47) | CA2CA1CA9MAPK1LMNA | |
| SCHEMBL858994 | 0.83 | CA1 (0.53) | CA2CA1CA9MAPK1LMNA | |
| SCHEMBL3150407 | 0.81 | TRPV4 (0.50) | CA2CA1CA9MAPK1LMNA | |
| SCHEMBL30504944 | 0.81 | TRPV4 (0.50) | CA2CA1CA9MAPK1LMNA | |
| SCHEMBL29020446 | 0.81 | SLC40A1 (0.38) | CA2CA1CA9MAPK1LMNA | |
| SCHEMBL2421543 | 0.80 | LMNA (0.44) | CA2CA1CA9MAPK1LMNA | |
| SCHEMBL2421539 | 0.79 | LMNA (0.43) | CA2CA1CA9MAPK1LMNA | |
| SCHEMBL31028665 | 0.75 | CA1 (0.56) | CA2CA1CA9MAPK1LMNA | |
| SCHEMBL20502571 | 0.75 | CA1 (0.56) | CA2CA1CA9MAPK1LMNA | |
| SCHEMBL27801396 | 0.74 | CA2 (0.47) | CA2CA1CA9MAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3891157-A1 | 4-AMINO OR 4-ALKOXY-SUBSTITUTED ARYL SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | Merck Sharp & Dohme Corp. (US) | 2021-10-13 | — | — | EP | claimed |
| WO-2020117626-A1 | 4-AMINO OR 4-ALKOXY-SUBSTITUTED ARYL SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2020-06-11 | — | — | WO | claimed |
| EP-2411388-A2 | PROCESS FOR THE PRODUCTION OF FUSED, TRICYCLIC SULFONAMIDES | Elan Pharmaceuticals Inc. (US) | 2012-02-01 | — | — | EP | claimed |
| WO-2010073011-A2 | COMPOUNDS USEFUL AS MEDICAMENTS | BETAGENON AB (SE) | 2010-07-01 | — | — | WO | claimed |
| EP-4558481-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | Biogen MA Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024020156-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023088233-A1 | LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2023-05-25 | — | — | WO | disclosed |
| EP-3959207-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | Celgene Corporation (US) | 2022-03-02 | — | — | EP | disclosed |
| EP-3891157-A1 | 4-AMINO OR 4-ALKOXY-SUBSTITUTED ARYL SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | Merck Sharp & Dohme Corp. (US) | 2021-10-13 | — | — | EP | disclosed |
| US-20200339559-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CELGENE CORPORATION | 2020-10-29 | — | — | US | disclosed |
| WO-2020117626-A1 | 4-AMINO OR 4-ALKOXY-SUBSTITUTED ARYL SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2020-06-11 | — | — | WO | disclosed |
| CN-108471751-A | Herbicidal compositions comprising 4-amino-3-chloro-6- (4-chloro-2-fluoro-3-methoxyphenyl) pyridine-2-carboxylic acid, florasulam and pyroxsulam or derivatives thereof | 美国陶氏益农公司 | 2018-08-31 | — | — | CN | disclosed |
| CN-103283747-B | A kind of Herbicidal combinations containing tribenuron-methyl and pyroxsulam | 青岛奥迪斯生物科技有限公司 | 2017-12-01 | — | — | CN | disclosed |
| CN-105248428-B | Herbicide combinations comprising a herbicide of the class of the diaminos-triazines | 拜耳知识产权有限责任公司 | 2017-11-14 | — | — | CN | disclosed |
| WO-2016173493-A1 | SULFONYLAMINOCARBONYL DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USES THEREOF | SHANGHAI DE NOVO PHARMATECH CO. LTD. (CN) | 2016-11-03 | — | — | WO | disclosed |
| EP-2411388-A2 | PROCESS FOR THE PRODUCTION OF FUSED, TRICYCLIC SULFONAMIDES | Elan Pharmaceuticals Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010073011-A2 | COMPOUNDS USEFUL AS MEDICAMENTS | BETAGENON AB (SE) | 2010-07-01 | — | — | WO | disclosed |
| US-20060293187-A1 | Herbicidal mixtures based on 3-phenyluracils | BASF AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339559-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CYP8B1, HAX1, HRH4 | CA2 3455/4885CA1 3844/4885CA9 3475/4885 |
| US-20060293187-A1 | Herbicidal mixtures based on 3-phenyluracils | CBR3, CYP2W1, DDT | CA2 1676/4885CA1 3305/4885CA9 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.